The Growing Aldosteronism Treatment Market: Opportunities and Innovations in 2025
Primary aldosteronism, once considered a rare endocrine disorder, has emerged as one of the most common causes of secondary hypertension, affecting up to 20% of patients with resistant high blood pressure. This growing recognition has sparked significant expansion in the aldosteronism treatment market, which is experiencing robust growth driven by improved diagnostic awareness, expanding treatment options, and increasing healthcare investments. Request a Sample: https://www.futurewiseresearch.com/contact.aspx?rpt=12973&type=requestsample Market Growth and Projections The aldosteronism treatment market is witnessing impressive growth trajectories across multiple forecasts. Recent market analyses indicate the sector is valued between $422.57 million to $1.12 billion in 2024, with projections showing substantial expansion through 2032-2033. The market is expected to grow at a compound annual growth rate (CAGR) of approximately 5.8% to 6.2%, potentially reaching $1.87 billi...